股票行情快报：天臣医疗（688013）2月6日主力资金净卖出427.86万元

Core Viewpoint - Tianchen Medical (688013) shows strong financial performance with significant revenue and profit growth in the first three quarters of 2025, indicating a positive outlook for the company in the high-end surgical stapler market [2]. Financial Performance - For the first three quarters of 2025, Tianchen Medical reported a main revenue of 244 million yuan, an increase of 20.66% year-on-year [2]. - The net profit attributable to shareholders reached 71.95 million yuan, up 68.29% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 66.20 million yuan, reflecting a 71.85% increase year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 87.66 million yuan, a 26.4% increase year-on-year [2]. - The quarterly net profit attributable to shareholders was 23.73 million yuan, up 70.74% year-on-year [2]. - The quarterly net profit after deducting non-recurring gains and losses was 21.92 million yuan, increasing by 72.61% year-on-year [2]. - The company's debt ratio stands at 11.3%, with investment income of 2.56 million yuan and financial expenses of -10.87 million yuan [2]. - The gross profit margin is reported at 63.22% [2]. Market Activity - As of February 6, 2026, Tianchen Medical's stock closed at 42.54 yuan, with a 1.45% increase [1]. - The trading volume was 11,100 hands, with a total transaction amount of 47.26 million yuan [1]. - On the same day, the net outflow of main funds was 4.28 million yuan, accounting for 9.05% of the total transaction amount, while retail investors saw a net inflow of 4.07 million yuan, representing 8.61% of the total [1]. Analyst Ratings - In the last 90 days, one institution has given a buy rating for Tianchen Medical [3].